Lorlatinib
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Lorlatinib: From Non-Small Cell Lung Cancer to Gingival Fibromatosis
One-Sentence Summary
Lorlatinib is a third-generation ALK/ROS1 tyrosine kinase inhibitor, originally used to treat ALK-positive non-small cell lung cancer (NSCLC). The TxGNN model's top-ranked prediction is gingival fibromatosis, but it rests on a computational score alone: 0 clinical trials and 0 publications support it. The evidence is at the model-prediction level only, and the recommendation is to hold.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Non-small cell lung cancer / lung cancer (from the knowledge graph; the Singapore licence text is blank) |
| Predicted New Indication | Fibromatosis, gingival |
| TxGNN Prediction Score | 99.81% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. From the literature, lorlatinib is a brain-penetrant, third-generation inhibitor of ALK and ROS1 tyrosine kinases. Its efficacy in ALK-positive NSCLC is well established, including in the Phase 3 CROWN study.
For gingival fibromatosis, no mechanistic link has been identified. No ALK/ROS1 involvement in this condition is established in the data, and the score of 0.998 is a computational output only. The other top predictions follow a similar pattern:
- Lung-related benign or rare tumours (fibroma of lung, hamartoma of lung, pulmonary sulcus neoplasm, lung benign neoplasm): these probably reflect the drug's association with lung disease rather than a disease-specific mechanism. Pancoast tumours are usually NSCLC, so ALK-positive cases might respond, but the data do not support this.
- Lung hilum carcinoma: this is essentially a variant of the approved ALK-positive lung cancer setting. It is supported by a single 2023 case report of pathological complete response after neoadjuvant lorlatinib.
- Lung germ cell tumour: the retrieved literature is mostly about ALK-driven neuroblastoma, a different disease. A Phase 1 trial there showed activity and could be assessed as a separate indication.
- Genetic or skin disorders (inclusion body myopathy with Paget disease, junctional epidermolysis bullosa, and a rare syndrome with leukomelanoderma): there is no plausible ALK/ROS1 mechanism. The literature retrieved for the syndrome consists of lorlatinib adverse-event reports, not therapeutic evidence.
Clinical Trial Evidence
Currently no related clinical trials registered for gingival fibromatosis. No clinical trials are registered for any of the top 10 predicted indications either.
Literature Evidence
Currently no related literature available for gingival fibromatosis.
The literature found for lower-ranked predictions does not support them as new indications. The most relevant items are listed below for context (the CROWN trial concerns the approved NSCLC indication, not a benign lung neoplasm):
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33207094 | 2020 | RCT (Phase 3 CROWN) | N Engl J Med | First-line lorlatinib vs crizotinib in advanced ALK-positive NSCLC |
| 38819031 | 2024 | RCT (5-year follow-up) | J Clin Oncol | Long-term progression-free survival and intracranial benefit of lorlatinib over crizotinib |
| 42217582 | 2026 | RCT update | Ann Oncol | 7-year update from CROWN; sustained long-term outcomes |
| 36535300 | 2023 | RCT (3-year update) | Lancet Respir Med | Updated efficacy and intracranial activity in CROWN |
| 39368244 | 2024 | Network meta-analysis | Lung Cancer | Lorlatinib compared with other ALK inhibitors as first-line therapy |
| 37012551 | 2023 | Phase 1 trial | Nat Med | Lorlatinib with or without chemotherapy in ALK-driven relapsed/refractory neuroblastoma (a different disease) |
| 37934724 | 2023 | Case report | Am J Case Rep | Neoadjuvant lorlatinib gave a pathological complete response in advanced ALK-positive lung cancer |
| 38554546 | 2024 | Review | Lung Cancer | Practical guide to managing lorlatinib adverse events |
| 40287137 | 2025 | Pharmacovigilance analysis | Endocr Pract | Lorlatinib-associated metabolic effects in the FAERS database |
| 40551396 | 2025 | Case report | Pediatr Blood Cancer | Pulmonary toxicity when lorlatinib is given with anti-GD2 antibody in neuroblastoma |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15830P | LORVIQUA FILM-COATED TABLET 25MG | Film-coated tablet | Not available in the compiled data |
| SIN15831P | LORVIQUA FILM-COATED TABLET 100MG | Film-coated tablet | Not available in the compiled data |
Both registrations are valid single-agent licences held by Pfizer Manufacturing Deutschland GmbH, and the route is oral.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (ALK/ROS1 tyrosine kinase inhibitor) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert. The literature highlights lipid levels (hyperlipidemia and dyslipidemia), CNS effects, and pulmonary toxicity as reported adverse events. |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
- Drug Interactions: 100 interactions were found in the DDInter database. Those listed here are the major ones; the remainder are moderate-level.
- Major: dexamethasone, clarithromycin
- Moderate (examples): hydrocortisone, triamcinolone, betamethasone, bupropion, aprepitant, morphine, cimetidine, alosetron, and several antidiabetic agents (dapagliflozin, empagliflozin, saxagliptin, linagliptin, glimepiride, chlorpropamide)
- Adverse events reported in the literature: hyperlipidemia and dyslipidemia, acute respiratory distress syndrome, drug-induced Sweet syndrome, metabolic effects (including weight gain), and pulmonary toxicity when combined with anti-GD2 antibody. These come from case reports and pharmacovigilance data, not label text.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction, gingival fibromatosis, has a high model score but no clinical trials, no literature, and no plausible ALK/ROS1 mechanism (evidence level L5). The strong Phase 3 evidence for lorlatinib belongs to its approved ALK-positive NSCLC indication and cannot be credited to the predicted indications.
To proceed, the following is needed:
- Mechanism of action data and any biological rationale linking ALK/ROS1 signalling to gingival fibromatosis
- Package insert warnings and contraindications from the HSA website (a blocking gap for safety screening)
- Approved indication text for the Singapore licences
- Preclinical or observational evidence for the predicted indication
- Separate assessment of ALK-driven neuroblastoma, which has Phase 1 clinical data, as a distinct candidate indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.